Development of a first in class inhibitor of BET bromodomains and dopamine receptor 2

被引：0
|
作者：
Yoshioka, Makoto
Chauhan, Jay
Fletcher, Steven
Strovel, Jeffrey W.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5062
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Development and preclinical assessment of a first-in-class small-molecule inhibitor of FLIP
    Higgins, Catherine A.
    Majkut, Joanna
    Fox, Jennifer
    Humphreys, Luke
    Fiedler, Greti Espona
    Boffey, Ray J.
    Perrior, Trevor R.
    Haigh, David
    Harrison, Timothy
    Longley, Daniel B.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [32] Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor
    Graham P Allaway
    Retrovirology, 3
  • [33] Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis
    Peyvandi, Flora
    Cannavo, Antonino
    Garagiola, Isabella
    Palla, Roberta
    Rosendaal, Frits
    Mannucci, Piermannuccio
    BLOOD, 2016, 128 (22)
  • [34] Development and characterization of a first-in-class small molecule inhibitor of PELP1
    Altwegg, Kristin A.
    Viswanadhapalli, Suryavathi
    Mann, Monica
    Pratap, Uday P.
    Li, Mengxing
    Liu, Junhao
    Luo, Yiliao
    Sareddy, Gangadhara R.
    Vankayalapati, Hariprasad
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2020, 80 (04)
  • [35] Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor
    Ku, Yi-Yin
    Chan, Vincent S.
    Christesen, Alan
    Grieme, Timothy
    Mulhern, Mathew
    Pu, Yu-Ming
    Wendt, Michael D.
    JOURNAL OF ORGANIC CHEMISTRY, 2019, 84 (08): : 4814 - 4829
  • [36] SEIZURE DEVELOPMENT AND DOPAMINE RECEPTOR SENSITIVITY
    SATO, M
    HIKASA, N
    TOMODA, T
    SUEMARU, K
    OTSUKI, S
    FOLIA PSYCHIATRICA ET NEUROLOGICA JAPONICA, 1978, 32 (03): : 343 - 344
  • [37] Dopamine D2 receptor regulates the functional development of retina
    Tian, Ning
    Xu, Hongping
    Wang, Ping
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [38] First-in-class: RGS protein inhibitor
    Kimple, A. J.
    Siderovski, D. P.
    MOLECULAR INTERVENTIONS, 2007, 7 (01) : 9 - 9
  • [39] Changes in Dopamine Release and Dopamine D2/3 Receptor Levels with the Development of Mild Obesity
    Kessler, Robert M.
    Zald, David H.
    Ansari, Mohammad Sib
    Li, Rui
    Cowan, Ronald L.
    SYNAPSE, 2014, 68 (07) : 317 - 320
  • [40] Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
    Stuhlmiller, Timothy J.
    Miller, Samantha M.
    Zawistowski, Jon S.
    Nakamura, Kazuhiro
    Beltran, Adriana S.
    Duncan, James S.
    Angus, Steven P.
    Collins, Kyla A. L.
    Granger, Deborah A.
    Reuther, Rachel A.
    Graves, Lee M.
    Gomez, Shawn M.
    Kuan, Pei-Fen
    Parker, Joel S.
    Chen, Xin
    Sciaky, Noah
    Carey, Lisa A.
    Earp, H. Shelton
    Jin, Jian
    Johnson, Gary L.
    CELL REPORTS, 2015, 11 (03): : 390 - 404
12345